Attached files
file | filename |
---|---|
EX-99.1 - ADDITIONAL EXHIBITS - Cellular Biomedicine Group, Inc. | cbmg_ex991000.htm |
8-K - CURRENT REPORT - Cellular Biomedicine Group, Inc. | cbmg_8k.htm |
Exhibit
99.2
Cellular Biomedicine Group (CBMG) Presents Poster of TCRs Targeting
AFP-Positive Liver Cancer at AACR Annual Meeting
NEW YORK, NY and SHANGHAI, China, June 22, 2020 –
Cellular Biomedicine Group Inc.
(NASDAQ: CBMG) (“CBMG” or the “Company”), a
biopharmaceutical firm engaged in the drug development of
immunotherapies for cancer and stem cell therapies for degenerative
diseases, today presented a poster during the 2020 American
Association for Cancer Research (AACR) annual meeting to be held as
a virtual meeting from June 22-24, 2020.
Poster Title:
|
“Selecting Clinical Lead of TCRs
Targeting Alpha-Fetoprotein-Positive Liver
Cancer on Balance of Risk and Benefit”
|
Session:
|
Session PO.IM02.04 -
Adoptive Cell Therapy 5
|
Poster No:
|
6589 (Board 1)
|
Authors:
|
Cellular Biomedicine Group, Inc, Gaithersburg, MD;
|
|
Georgia Cancer Center, Augusta University, Augusta, GA
|
Date:
|
Monday, June 22, 2020
|
Time:
|
9:00 a.m.to 6:00 p.m. EDT
|
Location:
|
San Diego Convention Center, Exhibit Halls A-F, Poster Virtual
Meeting II:
|
|
E-Posters
|
Website:
|
https://www.abstractsonline.com/pp8/#!/9045/presentation/7124
|
C-TCR055 is CBMG’s proprietary clinical lead of TCR-T
which specifically recognizes the HLA-A*02:01 restricted
AFP158-166
peptide that is highly expressed in hepatocellular carcinoma (HCC)
and other solid tumors. Preclinical studies suggested that C-TCR055
has optimal anti-tumor activities and a good safety profile. CBMG
is currently conducting a Phase I clinical study in unresectable
HCC in Fudan University Affiliated ZhongShang Hospital in Shanghai,
China (NCT03971747).
ABSTRACT
Background: Hepatocellular
carcinoma (HCC) is the most common type of primary liver cancer
with a poor prognosis and limited therapeutic options.
Alpha-fetoprotein (AFP), an established clinical biomarker of HCC,
has been employed as an attractive target for T cell-based
immunotherapy against this disease given its high expression in the
tumor and restricted expression in normal tissues. We have
identified a number of T cell receptors (TCRs) recognizing the
HLA-A*02:01 restricted AFP158-166 peptide
FMNKFIYEI, providing a TCR candidate pool for identifying TCRs with
optimal clinical benefit.
Methods: To select the
ideal AFP TCR for clinical use, we evaluated the efficacy and
safety profile of 7 TCRs on balance of their potency and
specificity by testing their reactivity to normal and transformed
cells covering a variety of primary cell types and HLA serotypes,
and potential protein candidate in human genome by an extensive
alanine scan (X-scan).
Results: We first selected
three TCR candidates based on the in vitro anti-tumor activity. Next we eliminated two
potential cross-reactive TCRs based on their reactivity against
normal and transformed cells covering a variety of primary cell
types and HLA serotypes, respectively. We then excluded the
potential cross-reactivity of the selected TCR with protein
candidates in human genome identified by
X-scan.
Conclusion: To date, we have
selected an
AFP TCR with the optimal affinity,
function, and safety profile, bearing properties that are expected
to allow AFP TCR redirected T cells to specifically differentiate
between AFP levels on tumor and normal tissues. An early phase
clinical trial using T cells transduced with this TCR to treat HCC
patients (NCT03971747) has been initiated.
About Cellular Biomedicine Group, Inc.
Cellular Biomedicine Group, Inc. (NASDAQ: CBMG) develops
proprietary cell therapies for the treatment of cancer and
degenerative diseases. The company conducts immuno-oncology and
stem cell clinical trials in China using products from its
integrated GMP laboratory. The Company’s GMP facilities in
China, consisting of twelve independent cell production lines, are
designed and managed according to both China and U.S. GMP
standards. Its Shanghai facility includes a “Joint Laboratory
of Cell Therapy” with GE Healthcare and a “Joint Cell
Therapy Technology Innovation and Application Center” with
Thermo Fisher Scientific. These partnerships focus on improving
manufacturing processes for cell therapies. CBMG currently has
ongoing CAR-T Phase I clinical trials in China. The China NMPA
(formerly CFDA) approved the Company’s IND application for a
Phase II trial for AlloJoin®, CBMG’s
“Off-the-Shelf” allogenic haMPC therapy for the
treatment of Knee Osteoarthritis (KOA), and has accepted the
Company’s IND application for a Phase II trial for
ReJoin® autologous haMPC therapy for the treatment of KOA. The
NMPA has also accepted CBMG’s dossier for an IND application
for clinical trials of anti-BCMA CAR-T. CBMG is included in the
broad-market Russell 3000® Index the small-cap Russell
2000® Index and the Loncar China BioPharma index. To learn
more about CBMG, please visit www.cellbiomedgroup.com.
Forward-Looking Statements
Statements in this press release relating to plans, strategies,
specific activities, and other statements that are not descriptions
of historical facts may be forward-looking statements within the
meaning of the Private Securities Litigation Reform Act of 1995,
Section 27A of the Securities Act of 1933, as amended, and Section
21E of the Securities Exchange Act of 1934, as amended.
Forward-looking information is inherently subject to risks and
uncertainties, and actual results could differ materially from
those currently anticipated due to a number of factors, which
include any risks detailed from time to time in CBMG’s
reports filed with the Securities and Exchange Commission, Annual
Reports on Form 10-K, Quarterly Reports on Form 10-Q, and Current
Reports on Form 8-K, including risks relating to the impact of the
COVID-19 pandemic on our operations, including risks associated
with the evolving COVID-19 pandemic and actions taken in response
to it. Generally, the words “believes,”
“anticipates,” “may,” “will,”
“should,” “could,” “expect,”
“plans,” “intend,” “estimate,”
“projects,” “presents,”
“potential,” “continue” and similar
expressions or the negative thereof or comparable terminology are
intended to identify forward-looking statements. These statements
reflect our current views with respect to future
events or
to our future activities and involve known and unknown risks,
uncertainties and other factors which may cause our actual
activities, actions or achievements to be materially different from
any future activities, actions or achievements expressed or implied
by the forward-looking statements. Given these uncertainties, you
should not place undue reliance on these forward-looking
statements.
Company Contact:
Derrick C. Li
Head of Strategy and Investor Relations, CBMG
Phone: 917-717-0994
Email: derrick.li@cellbiomedgroup.com